Paper37675271
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
Li R and 11 others. JHEP Rep, 2023. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies. Papers, record 37675271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37675271
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26563120 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. | Hepatol Int | 2016 | https://conductscience.org/library/papers/26563120 | PubMed |
| 2 | 27615026 | Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. | Lancet Infect Dis | 2016 | https://conductscience.org/library/papers/27615026 | PubMed |
| 3 | 16530509 | Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. | Gastroenterology | 2006 | https://conductscience.org/library/papers/16530509 | PubMed |
| 4 | 25164003 | The global burden of liver disease: the major impact of China. | Hepatology | 2014 | https://conductscience.org/library/papers/25164003 | PubMed |
| 5 | 34642494 | Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. | Nat Med | 2021 | https://conductscience.org/library/papers/34642494 | PubMed |
| 6 | 35738290 | Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35738290 | PubMed |
| 7 | 30992636 | Countdown to 2030: eliminating hepatitis B disease, China. | Bull World Health Organ | 2019 | https://conductscience.org/library/papers/30992636 | PubMed |
| 8 | 25530442 | Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Lancet | 2015 | https://conductscience.org/library/papers/25530442 | PubMed |
| 9 | 16391218 | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. | JAMA | 2006 | https://conductscience.org/library/papers/16391218 | PubMed |
| 10 | 26725905 | The prognosis and management of inactive HBV carriers. | Liver Int | 2016 | https://conductscience.org/library/papers/26725905 | PubMed |
| 11 | 24954675 | Hepatitis B virus infection. | Lancet | 2014 | https://conductscience.org/library/papers/24954675 | PubMed |
| 12 | 35063115 | Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. | Lancet Glob Health | 2022 | https://conductscience.org/library/papers/35063115 | PubMed |
| 13 | 26566246 | Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. | Hepatology | 2016 | https://conductscience.org/library/papers/26566246 | PubMed |
| 14 | 33658732 | Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. | Bull World Health Organ | 2021 | https://conductscience.org/library/papers/33658732 | PubMed |
| 15 | 34711822 | The impact of the timely birth dose vaccine on the global elimination of hepatitis B. | Nat Commun | 2021 | https://conductscience.org/library/papers/34711822 | PubMed |
| 16 | 32255486 | Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32255486 | PubMed |
| 17 | 34590058 | Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. | Lancet Reg Health West Pac | 2021 | https://conductscience.org/library/papers/34590058 | PubMed |
| 18 | 29072546 | Socioeconomic inequality in Hepatitis B vaccination of rural adults in China. | Hum Vaccin Immunother | 2018 | https://conductscience.org/library/papers/29072546 | PubMed |
| 19 | 29307467 | Hepatocellular carcinoma. | Lancet | 2018 | https://conductscience.org/library/papers/29307467 | PubMed |
| 20 | 29877316 | Hepatitis B virus infection. | Nat Rev Dis Primers | 2018 | https://conductscience.org/library/papers/29877316 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42337522 | Forecasting monthly hepatitis B cases in China: a nationwide comparative study based on surveillance data. | BMC Public Health | 2026 | https://conductscience.org/library/papers/42337522 | PubMed |
| 42328238 | Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children. | Infect Dis Immun | 2024 | https://conductscience.org/library/papers/42328238 | PubMed |
| 41127124 | Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study. | Infect Dis Model | 2026 | https://conductscience.org/library/papers/41127124 | PubMed |
| 41035085 | Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control. | Glob Health Res Policy | 2025 | https://conductscience.org/library/papers/41035085 | PubMed |
| 40937078 | Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/40937078 | PubMed |
| 40487768 | Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B. | Infect Dis Model | 2025 | https://conductscience.org/library/papers/40487768 | PubMed |
| 40127642 | Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on "Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial". | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/40127642 | PubMed |
| 40104634 | Modeling hepatitis B-related deaths in China to achieve the WHO's impact target. | Infect Dis Model | 2025 | https://conductscience.org/library/papers/40104634 | PubMed |
| 40044428 | [Recent advances in epidemiology, prevention and treatment of hepatitis B in China]. | Zhonghua Gan Zang Bing Za Zhi | 2025 | https://conductscience.org/library/papers/40044428 | PubMed |
| 39961977 | Expanding treatment indications in chronic hepatitis B: Should we treat all patients? | Hepatol Int | 2025 | https://conductscience.org/library/papers/39961977 | PubMed |
| 39957746 | Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China. | Liver Res | 2024 | https://conductscience.org/library/papers/39957746 | PubMed |
| 39767809 | Correlation Between Clinical Indicators and Liver Pathology in Children with Chronic Hepatitis B. | Biomedicines | 2024 | https://conductscience.org/library/papers/39767809 | PubMed |
| 39069723 | Correspondence to editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study". | Clin Mol Hepatol | 2024 | https://conductscience.org/library/papers/39069723 | PubMed |
| 38858193 | [Research progress on clinical antiviral treatment of chronic hepatitis B in children]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/38858193 | PubMed |
| 38393523 | The History of Controlling and Treating Infectious Diseases in Ancient China. | Curr Med Sci | 2024 | https://conductscience.org/library/papers/38393523 | PubMed |
| 38313234 | Antiviral treatment standards for hepatitis B: An urgent need for expansion. | World J Gastroenterol | 2024 | https://conductscience.org/library/papers/38313234 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37675271
GET https://conductscience.org/api/papers/v1/37675271/references?page=2